P2RY12 and COVID-19: Additionally, the ACTIV-4a trial with P2Y12 inhibition treatment in non-critically ill patients with COVID-19 demonstrated that the addition of P2Y12 inhibition to therapeutic-dose heparin did not decrease the trend of all-cause death or increase the proportion of survival to hospital discharge compared with only therapeutic anticoagulation.